356 related articles for article (PubMed ID: 16141567)
21. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes.
Nakajima M; Inoue T; Shimada N; Tokudome S; Yamamoto T; Kuroiwa Y
Drug Metab Dispos; 1998 Mar; 26(3):261-6. PubMed ID: 9492390
[TBL] [Abstract][Full Text] [Related]
22. A screening study on the liability of eight different female sex steroids to inhibit CYP2C9, 2C19 and 3A4 activities in human liver microsomes.
Laine K; Yasar U; Widén J; Tybring G
Pharmacol Toxicol; 2003 Aug; 93(2):77-81. PubMed ID: 12899669
[TBL] [Abstract][Full Text] [Related]
23. Metabolism of (+)- and (-)-limonenes to respective carveols and perillyl alcohols by CYP2C9 and CYP2C19 in human liver microsomes.
Miyazawa M; Shindo M; Shimada T
Drug Metab Dispos; 2002 May; 30(5):602-7. PubMed ID: 11950794
[TBL] [Abstract][Full Text] [Related]
24. No inhibition of cytochrome P450 activities in human liver microsomes by sulpiride, an antipsychotic drug.
Niwa T; Inoue S; Shiraga T; Takagi A
Biol Pharm Bull; 2005 Jan; 28(1):188-91. PubMed ID: 15635191
[TBL] [Abstract][Full Text] [Related]
25. Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro.
Ufer M; Svensson JO; Krausz KW; Gelboin HV; Rane A; Tybring G
Eur J Clin Pharmacol; 2004 May; 60(3):173-82. PubMed ID: 15054565
[TBL] [Abstract][Full Text] [Related]
26. In-vitro metabolism of glycyrrhetinic acid by human and rat liver microsomes and its interactions with six CYP substrates.
Zhao K; Ding M; Cao H; Cao ZX
J Pharm Pharmacol; 2012 Oct; 64(10):1445-51. PubMed ID: 22943175
[TBL] [Abstract][Full Text] [Related]
27. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes.
Ramírez J; Innocenti F; Schuetz EG; Flockhart DA; Relling MV; Santucci R; Ratain MJ
Drug Metab Dispos; 2004 Sep; 32(9):930-6. PubMed ID: 15319333
[TBL] [Abstract][Full Text] [Related]
28. Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes.
Taavitsainen P; Anttila M; Nyman L; Karnani H; Salonen JS; Pelkonen O
Pharmacol Toxicol; 2000 May; 86(5):215-21. PubMed ID: 10862503
[TBL] [Abstract][Full Text] [Related]
29. Effects of irsogladine on P450-isoform specific activities in human hepatic microsomes.
Nakamura A; Tougou K; Kitazumi H; Yamada T; Honjou K; Nonaka K; Mukai H
Arzneimittelforschung; 2006; 56(7):547-52. PubMed ID: 16927538
[TBL] [Abstract][Full Text] [Related]
30. Validation of (-)-N-3-benzyl-phenobarbital as a selective inhibitor of CYP2C19 in human liver microsomes.
Cai X; Wang RW; Edom RW; Evans DC; Shou M; Rodrigues AD; Liu W; Dean DC; Baillie TA
Drug Metab Dispos; 2004 Jun; 32(6):584-6. PubMed ID: 15155548
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase.
Grimm SW; Dyroff MC
Drug Metab Dispos; 1997 May; 25(5):598-602. PubMed ID: 9152599
[TBL] [Abstract][Full Text] [Related]
32. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.
Hyland R; Roe EG; Jones BC; Smith DA
Br J Clin Pharmacol; 2001 Mar; 51(3):239-48. PubMed ID: 11298070
[TBL] [Abstract][Full Text] [Related]
33. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole.
Hyland R; Jones BC; Smith DA
Drug Metab Dispos; 2003 May; 31(5):540-7. PubMed ID: 12695341
[TBL] [Abstract][Full Text] [Related]
34. Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: application of the relative activity factor approach.
Venkatakrishnan K; von Moltke LL; Greenblatt DJ
J Pharm Sci; 1998 Jul; 87(7):845-53. PubMed ID: 9649353
[TBL] [Abstract][Full Text] [Related]
35. Isoform selective inhibition and inactivation of human cytochrome P450s by methylenedioxyphenyl compounds.
Nakajima M; Suzuki M; Yamaji R; Takashina H; Shimada N; Yamazaki H; Yokoi T
Xenobiotica; 1999 Dec; 29(12):1191-202. PubMed ID: 10647906
[TBL] [Abstract][Full Text] [Related]
36. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes.
Karam WG; Goldstein JA; Lasker JM; Ghanayem BI
Drug Metab Dispos; 1996 Oct; 24(10):1081-7. PubMed ID: 8894508
[TBL] [Abstract][Full Text] [Related]
37. In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene.
Taavitsainen P; Juvonen R; Pelkonen O
Drug Metab Dispos; 2001 Mar; 29(3):217-22. PubMed ID: 11181487
[TBL] [Abstract][Full Text] [Related]
38. Substrate Specificity of Human Cytochrome P450 (CYP) 2C Subfamily and Effect of Azole Antifungal Agents on CYP2C8.
Niwa T; Imagawa Y
J Pharm Pharm Sci; 2016; 19(4):423-429. PubMed ID: 28057172
[TBL] [Abstract][Full Text] [Related]
39. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions.
Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K
Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A.
Jeong S; Nguyen PD; Desta Z
Antimicrob Agents Chemother; 2009 Feb; 53(2):541-51. PubMed ID: 19029318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
